Ennogen Healthcare International Ltd will take on responsibility for the marketing, sale and supply of Capsaicin 0.075% (Axsain) and 0.025% (Zacin) cream and all other associated activities once the marketing authorisations and trademarks are transferred.

After a thorough review, the Teva UK decision to divest Capsaicin 0.075% (Axsain) and 0.025% (Zacin) cream to Ennogen Healthcare International Ltd has been taken in alignment with their Pivot to Growth strategy.

Ennogen Healthcare International Limited will make best efforts to bring back Capsaicin 0.075% (Axsain) and 0.025% (Zacin) cream into stock in February 2026. Please contact Ennogen Healthcare Ltd on +44 (0) 1322 629 220 or info@ennogen.com ­­­­­­­­­for information about future supply of this product.